
Garlic (Allium sativum L.) contains phytochemicals of potential relevance to oxidative stress reduction and glucose homeostasis. This study characterised aqueous Allium sativum extract and evaluated its antioxidant, antiglycation and antidiabetic effects in alloxan-induced diabetic Sprague–Dawley rats, together with molecular docking against human alpha-amylase. Mineral composition, FTIR, GC–MS and phytochemical profiles were determined, while antioxidant and antiglycation activities were assessed using established in-vitro assays. Twenty-five rats were allocated to five groups. Diabetic animals received no treatment, glibenclamide (10 mg/kg), or aqueous garlic extract at 250 or 500 mg/kg body weight for 15 days, while a non-diabetic group served as the normal control. GC–MS identified 22 compounds, with 4H-pyran-4-one,2,3-dihydro-3,5-dihydroxy-6-methyl accounting for 22.53% and diallyl disulfide for 17.05%. The extract showed DPPH radical-scavenging activity with an IC₅₀ of 66.67 ± 2.07 µg/mL and inhibited advanced glycation end-product formation with an IC₅₀ of 66.75 ± 0.76 µg/mL. Treatment with the extract was associated with reduced blood glucose, total cholesterol, triglycerides, LDL-cholesterol, atherogenic indices and malondialdehyde, together with increases in HDL-cholesterol and antioxidant parameters compared with untreated diabetic animals. Pancreatic histology also showed better-preserved islet architecture in extract-treated groups. Molecular docking against human alpha-amylase (PDB: 1U2Y) yielded a binding affinity of −5.9 kcal/mol for the highest-ranked garlic-derived ligand (Hydrazine,1,2-dimethyl-), compared with −6.3 kcal/mol for acarbose. Overall, the findings indicate antioxidant, antiglycation and glucose-lowering activity of aqueous garlic extract in this experimental model.
Background: Atypical bacterial pathogens are recognised causes of community-acquired pneumonia (CAP), but contemporary data regarding their frequency and clinical significance among adults hospitalised with CAP in India are limited. Aim: This study examined atypical-pathogen positivity and compared clinical severity and early outcomes according to test results. Methods: A prospective observational study was conducted among adults hospitalised with CAP through the emergency department of a tertiary-care centre in North India from January to July 2024. Patients were tested for Mycoplasma pneumoniae and Chlamydia pneumoniae using serological assays and for Legionella pneumophila serogroup 1 using urinary antigen testing. Disease severity, organ-support requirements, and clinical outcomes through day 7 were compared according to atypical-pathogen positivity. Results: Among 50 patients, 5 (10.0%; 95% CI, 3.3–21.8) had laboratory evidence of an atypical bacterial pathogen: 4 (8.0%) had M. pneumoniae and 1 (2.0%) had C. pneumoniae; none tested positive for L. pneumophila. Severe CAP was present in 3/5 atypical-positive patients (60.0%) and 12/45 atypical-negative patients (26.7%) (risk ratio, 2.25; 95% CI, 0.95–5.34). Ventilatory support was required in 3/5 (60.0%) and 5/45 (11.1%), respectively (risk ratio, 5.40; 95% CI, 1.81–16.11), and invasive mechanical ventilation was required in 3/5 (60.0%) and 3/45 (6.7%), respectively (risk ratio, 9.00; 95% CI, 2.44–33.24). Vasopressor support was required in 40.0% and 11.1%, respectively. By day 7, clinical worsening occurred in 40.0% of atypical-positive and 24.4% of atypical-negative patients. No deaths occurred among atypical-positive patients; 3 of 45 atypical-negative patients (6.7%) died. Conclusions: In this prospective cohort of adults hospitalised with CAP, 10% had laboratory evidence of an atypical bacterial pathogen, predominantly M. pneumoniae. Atypical-pathogen positivity was observed in patients with severe illness and was associated with a greater observed requirement for ventilatory support. Given the small number of positive cases and wide confidence intervals, these findings are hypothesis-generating and require confirmation in larger studies using molecular diagnostics.
Background: Angiogenic signalling is biologically relevant to polycystic ovary syndrome (PCOS) and placental adaptation, but evidence linking VEGFA sequence variants to reproductive complications is inconsistent. Obesity may complicate interpretation of such genetic studies. Objective: To examine whether aggregated VEGFA rs2010963 (−634G>C) genotype distributions differed between an obesity-stratified study group and a comparison group, and across three obesity grades. Methods: We reanalysed genotype counts supplied in three summary tables. The obesity-stratified group included 60 individuals (grade I, n=25; grade II, n=30; grade III, n=5); the comparison group included 50. Allele frequencies were reconstructed from diploid genotype counts. Exact Hardy–Weinberg equilibrium (HWE) tests, Fisher tests for binary genotype contrasts, and Monte Carlo Fisher–Freeman–Halton tests for multi-category tables were used. No patient-level pregnancy or PCOS-status records were available for this genetic dataset. Results: GG, GC and CC genotypes occurred in 42 (70.0%), 15 (25.0%) and 3 (5.0%) participants in the obesity-stratified group versus 30 (60.0%), 18 (36.0%) and 2 (4.0%) in the comparator. The overall 2×3 genotype comparison was not statistically significant (Monte Carlo exact P=0.464). The odds ratio for GG versus GC/CC was 1.56 (95% CI 0.71–3.43; Fisher P=0.317). Variation across obesity grades was not statistically conclusive (3×3 exact Monte Carlo P=0.118). In grade III obesity, the sample comprised only five individuals. Conclusion: These aggregate data do not establish a reproducible association between rs2010963 and obesity grade. They support careful design of future studies integrating validated PCOS phenotyping, angiogenic biomarkers and pregnancy outcomes; they cannot substantiate a clinical prediction or prevention algorithm.
Background: Implant surface characteristics and the timing of prosthetic loading are relevant to early peri-implant bone-level changes. This prospective study compared radiographic mesial marginal bone loss around calcium-coated and conventional dental implants managed under two loading schedules. Methods: Forty systemically healthy partially edentulous patients were allocated to four groups (n = 10 each): calcium-coated or conventional implants treated under a shorter postoperative loading schedule (Groups I and II, respectively), and calcium-coated or conventional implants scheduled for loading at approximately three weeks (Groups III and IV, respectively). Mesial marginal bone levels were measured on digital intraoral periapical radiographs at baseline and at nominal 3-, 6-, 9-, and 12-week follow-ups. Group means and standard deviations were summarised descriptively. Results: At 12 weeks, mean (SD) mesial marginal bone loss was 0.46 (0.02) mm in Group I, 0.61 (0.02) mm in Group II, 0.36 (0.03) mm in Group III, and 0.46 (0.04) mm in Group IV. Mean bone loss increased with time in each group. Within each loading schedule, the calcium-coated group had a numerically lower 12-week mean than the corresponding conventional-implant group. Conclusion: This four-group comparison documents the short-term trajectory of mesial marginal bone loss after implant placement and loading. The descriptive findings provide a basis for further evaluation of implant surface chemistry and loading schedule in adequately characterised longitudinal studies.
Background: Giant cell tumour of bone (GCTB) is a locally aggressive neoplasm that may recur after treatment and, in uncommon cases, metastasise to the lungs. This report describes pulmonary metastases following recurrent GCTB of the proximal tibia. Case Presentation: A 43-year-old man had previously undergone curettage and bone cement filling for GCTB of the right proximal tibia. Local recurrence developed one year after the initial diagnosis and was treated with subcutaneous denosumab for five months. The patient discontinued treatment without medical advice. Subsequent enlargement of the recurrent mass prompted further imaging and lower-limb amputation. Approximately one year later, he presented with progressive dyspnoea and persistent cough. Chest imaging demonstrated a left mediastinal–pulmonary mass and multiple lesions with a cannonball appearance. Flexible bronchoscopy showed no endobronchial tumour. Histopathological examination of a computed tomography-guided transthoracic needle biopsy identified mononuclear stromal cells and multinucleated giant cells, supporting pulmonary metastasis from GCTB. Clinical and radiological assessment found no recurrence at the amputation site. Following multidisciplinary review, denosumab was selected for further treatment. Conclusion: This case illustrates pulmonary metastatic disease following recurrent proximal tibial GCTB despite extensive local treatment. It supports consideration of continued clinical surveillance and individualised assessment of pulmonary lesions. The temporal association between treatment discontinuation and disease progression does not establish causality.